Journal article icon

Journal article

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.

Abstract:

Bisphosphonates (BPs) are widely used in the treatment of osteolytic bone disease associated with multiple myeloma, and have been demonstrated to exert antitumor effects both in vitro and in vivo. However, the precise molecular mechanisms involved in the direct antitumor effects of BPs in vitro are not known. Nitrogen-containing BPs, such as risedronate (RIS), act by inhibiting protein prenylation. A phosphonocarboxylate analogue of RIS, 3-PEHPC, has previously been shown in osteoclasts and m...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/ijc.21977

Authors


Roelofs, AJ More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Ebetino, FH More by this author
Russell, RG More by this author
Expand authors...
Journal:
International journal of cancer. Journal international du cancer
Volume:
119
Issue:
6
Pages:
1254-1261
Publication date:
2006-09-05
DOI:
EISSN:
1097-0215
ISSN:
0020-7136
URN:
uuid:cbc92d9b-4a5d-4b61-9d39-eac23bbf4361
Source identifiers:
107556
Local pid:
pubs:107556

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP